Kemp Anna, Preen David B, Glover John, Semmens James, Roughead Elizabeth E
School of Population Health, The University of Western Australia, Crawley, WA 6009, Australia.
Aust Health Rev. 2011 Aug;35(3):341-9. doi: 10.1071/AH10906.
To determine changes in out-of-pocket expenditure on prescription medicines for Australian patients, and how patient expenditure compares with other Organisation for Economic Co-operation and Development (OECD) countries.
We examined out-of-pocket expenditure on prescription medicines by patients in Australia between 1970 and 2007, and between Australia and 15 other OECD countries (Canada, Czech Republic, Denmark, Finland, France, Germany, Japan, Republic of Korea (South Korea), Luxembourg, Poland, Slovak Republic, Spain, Sweden, Switzerland and the United States) in 2005.
Spending on publicly subsidised medicines by Australian patients increased from $16 per person in 1971 to $62 in 2007. Patient expenditure on all prescription medicines had risen to $134 per person in 2007. Out-of-pocket expenditure for Australian patients ranked 4th of 14 OCED countries with universal pharmaceutical subsidies. Australian patients pay 28% of national pharmaceutical expenditure; more than patients in South Korea (27%), Slovak Republic (26%), Sweden (22%), France, Luxembourg, Japan and Switzerland (17%), Germany (15%), Czech Republic (11%) and Spain (6%), but less than patients in Finland (36%), Denmark (33%) and Poland (34%).
Compared to other OECD countries, Australian out-of-pocket costs are now in the mid to upper range. Further increases have the potential to significantly affect access to care.
确定澳大利亚患者在处方药方面自付费用的变化情况,以及患者支出与经济合作与发展组织(经合组织)其他国家相比如何。
我们研究了1970年至2007年澳大利亚患者在处方药方面的自付费用,以及2005年澳大利亚与其他15个经合组织国家(加拿大、捷克共和国、丹麦、芬兰、法国、德国、日本、大韩民国(韩国)、卢森堡、波兰、斯洛伐克共和国、西班牙、瑞典、瑞士和美国)的情况。
澳大利亚患者在政府补贴药品上的支出从1971年的人均16美元增加到2007年的62美元。2007年患者在所有处方药上的支出已升至人均134美元。在14个实行全民药品补贴的经合组织国家中,澳大利亚患者的自付费用排名第四。澳大利亚患者支付国家药品支出的28%;高于韩国患者(27%)、斯洛伐克共和国患者(26%)、瑞典患者(22%)、法国、卢森堡、日本和瑞士患者(17%)、德国患者(15%)、捷克共和国患者(11%)和西班牙患者(6%),但低于芬兰患者(36%)、丹麦患者(33%)和波兰患者(34%)。
与经合组织其他国家相比,澳大利亚目前的自付费用处于中高范围。进一步增加可能会对医疗服务的可及性产生重大影响。